Fred Alger Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Fred Alger Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-15,925	Closed	-$313K	–	579
2022 Q3	$313K	Buy	+15,925	New	+$319K	﹤0.01%	417
2015 Q4	–	Sell	-2,320	Closed	-$225K	–	600
2015 Q3	$225K	Sell	2,320 -11,382	-83%	-$1.36M	﹤0.01%	463
2015 Q2	$2.08M	Buy	+13,702	New	+$2.26M	0.01%	386

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Fred Alger Management's KDNY Position: Q4 2022 in Review

Fred Alger Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2022, closing a stake of 15,925 shares — an estimated $313K sold.

Fred Alger Management first reported a position in KDNY in Q2 2015 and held it in 3 quarters. The position peaked at $2.08M in Q2 2015. 155 funds tracked by Wall St. Rank hold KDNY as of Q4 2022.

Fred Alger Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Fred Alger Management sold 15,925 Chinook Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $313K.
Fred Alger Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 3 quarters.
Fred Alger Management's Chinook Therapeutics, Inc. Common Stock position peaked at $2.08M in Q2 2015.
155 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Fred Alger Management's 13F filing for Q4 2022, filed 14 Feb 2023.